The VanEck Biotech ETF (BBH) is recommended as a Buy due to its focused exposure to top biotech companies like Amgen, Gilead, and Vertex, which are entering a new growth phase. These firms support capital growth through diverse drug pipelines, strong cash flows, and expansion into new therapeutic areas. Despite a higher expense ratio and low dividend yield, BBH offers an attractive risk-reward profile with reasonable valuation compared to its growth prospects. The ETF is expected to potentially outperform its long-term average and possibly the S&P 500 through 2027, making it appealing for long-term investors seeking growth in biotech.
The Schwab U.S. Dividend Equity ETF (SCHD) has defied bearish macroeconomic conditions by delivering strong returns, largely due to its top holdings such as Abbott Laboratories (ABT), Merck (MRK), and Amgen (AMGN) which posted significant gains after...
In 2026, Merck's stock surged 44% year-to-date, outperforming major U.S. drugmakers Amgen (up 35%) and Pfizer (up 14%). Merck's success is driven by its strong oncology portfolio, including the top-selling cancer drug KEYTRUDA, and diverse products b...
